Last reviewed · How we verify
Jintrolong® high dose group — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Jintrolong® high dose group (Jintrolong® high dose group) — Changchun GeneScience Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Jintrolong® high dose group TARGET | Jintrolong® high dose group | Changchun GeneScience Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Jintrolong® high dose group CI watch — RSS
- Jintrolong® high dose group CI watch — Atom
- Jintrolong® high dose group CI watch — JSON
- Jintrolong® high dose group alone — RSS
Cite this brief
Drug Landscape (2026). Jintrolong® high dose group — Competitive Intelligence Brief. https://druglandscape.com/ci/jintrolong-high-dose-group. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab